Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine adjunctive treatment for obsessive-compulsive disorder
IRCT20260426069173N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Escitalopram + agomelatine with Escitalopram + placebo (2 arms). Primary endpoints: Change in Yale-Brown Obsessive-Compulsive Scale score, Adverse drug effects and 1 more. Started Apr 2026; status: completed.
02
Drugs
agomelatine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20260426069173N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260426069173N1.